Evicenter
Xolair (omalizumab) in Allergic asthma
Manufacturer
Genentech, Inc.; Novartis Pharmaceuticals Corporation
Prescribing information
Xolair (opens in a new tab)
Questions
38
Last updated

All questions

Clinical trials: Xolair (omalizumab) in allergic asthma

8 questions · 2 sources

Clinical trials

How were the Xolair allergic asthma trials designed (Studies 1 and 2)?

Study results

How much did Xolair reduce asthma exacerbations vs placebo (Trials 1 and 2)?

Note: The table text lists each row's values in the header order: Asthma Trial 1 XOLAIR (N=268), Asthma Trial 1 placebo (N=257), Asthma Trial 2 XOLAIR (N=274), Asthma Trial 2 placebo (N=272). The stable steroid phase lasted 16 weeks and the steroid reduction phase 12 weeks.

Does Xolair improve asthma symptoms and FEV1 vs placebo (Trial 1)?

Note: Table 12 lists, for each endpoint, the XOLAIR mean baseline and median change to Week 16, then the placebo mean baseline and median change.

Does Xolair reduce asthma hospitalizations?

Did Xolair reduce exacerbations in severe asthma on high-dose steroids (Trial 3)?

Note: Table 13 lists each row's values in the header order: inhaled corticosteroids only, XOLAIR (N=126) and placebo (N=120); oral plus inhaled corticosteroids, XOLAIR (N=50) and placebo (N=45). Both phases lasted 16 weeks.

Which asthma patients did not have fewer exacerbations on Xolair?

Pediatric efficacy

How much did Xolair reduce exacerbations in children 6 to 11 (Trial 4)?

Did Xolair reduce exacerbations in children with well-controlled asthma (Trial 5)?

Note: The label describes Asthma Trial 5 as a study that primarily evaluated safety.